Ex-PRESS® implant as the first surgical option in the iridocorneal endothelial syndrome.
Arch Soc Esp Oftalmol (Engl Ed)
; 96(8): 430-433, 2021 Aug.
Article
en En
| MEDLINE
| ID: mdl-34340781
ABSTRACT
Our purpose is to report the intermediate-term results of the Ex-PRESS® implant as the first surgical option in patients with Iridocorneal Endothelial (ICE) Syndrome. We describe two patients diagnosed from ICE syndrome with medically uncontrolled glaucoma and finally treated with an Ex-PRESS® implant, associating a cataract surgery in one of them. Three years after surgery, intraocular pressure remains stable without any additional medical antiglaucomatous treatment, with a well-located implant surrounded by a diffuse filtering bleb and no sight-threatening adverse events have been documented. In addition, no progression of the disease has been registered. This report encourage the Ex-PRESS® implant to be considered the first surgical option in this patients as it allows a permeable ostium in spite of the progressive synechial angle closure typical of the ICE syndrome.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Implantes de Drenaje de Glaucoma
/
Síndrome Endotelial Iridocorneal
Tipo de estudio:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Arch Soc Esp Oftalmol (Engl Ed)
Año:
2021
Tipo del documento:
Article